Darlene Dobkowski, MA

Fixed-duration glofitamab combined with polatuzumab vedotin achieved high response rates and sustained remissions in heavily pretreated relapsed/refractory large B-cell lymphoma.

An all-oral regimen combining revumenib with decitabine/cedazuridine (ASTX727) and venetoclax reached high remission rates in patients with acute myeloid leukemia with certain genetic alterations.

The GigaPath AI model was highlighted for its advanced capabilities in predicting cancer mutations and tumor mutation burden, including those in lung cancer and other malignancies.

The phase 3 HypoG-01 trial found moderately hypofractionated radiation therapy had similar lymphedema risk to standard therapy in patients with early breast cancer.

Adding relatlimab to nivolumab and chemotherapy improved clinical benefit in patients with stage IV non–small cell lung cancer compared to nivolumab and chemotherapy alone.

In a 10-year analysis of the ShortHER trial, high tumor-infiltrating lymphocytes were associated with improved survival in patients with early HER2-positive breast cancer treated with adjuvant chemotherapy and trastuzumab.

The first safety run-in cohort of the MajesTEC-7 trial showed promising safety/efficacy results with teclistamab, daratumumab, and lenalidomide in newly diagnosed multiple myeloma.

Improved results were seen with subcutaneous amivantamab vs its intravenous formulation in patients with refractory EGFR-mutated, advanced non-small lung cancer had improved responses with low rates of adverse effects with subcutaneous amivantamab vs its intravenous formulation.

A study has shown artificial intelligence virtual navigation to be a promising tool to improve colonoscopy completion rates, with high patient acceptance.

Patients with metastatic hormone-sensitive prostate cancer treated with darolutamide plus androgen deprivation therapy and docetaxel had lower rates of hospitalizations but marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy, and docetaxel.

From 2013 to 2022, the use of FOLFOXIRI plus bevacizumab increased in patients with metastatic colorectal cancer, with a trend in patients aged 50 years and younger.

The 3-year final analysis of efficacy and safety of the REACH3 trial showed that patients with steroid refractory or dependent chronic graft-versus-host disease benefited more with ruxolitinib compared with best available treatment.

Compared with CAR T-cell therapy, autologous hematopoietic cell transplantation resulted in lower relapse rates and improved progression-free survival in patients with relapsed large B-cell lymphoma while they were in complete response.

Four outpatient chimeric antigen receptor T-cell therapy programs utilized a virtual care program including remote patient monitoring following T-cell infusion, reducing hospital admissions and helping patients contact nurses during non-clinical hours.

Idecabtagene vicleucel improved health-related quality of life compared with standard regimens in patients with triple-class exposed, relapsed/refractory multiple myeloma.

An expert discussed how the use of circulating tumor DNA in patients with RCC may help guide whether treatment should be intensified or deescalated.

Patients with advanced clear cell renal cell carcinoma treated with zanzalintinib had experienced promising antitumor activity with manageable toxicity regardless of prior treatment with cabozantinib.

An expert discussed how recent studies in patients with translocation RCC, a rare type of RCC, have demonstrated that the disease responds well to immune checkpoint inhibitors, but more focus is needed on novel targets to treat it.

Findings from the FLAURA2 trial demonstrate that firstline treatment with osimertinib plus chemotherapy reduced the risk for central nervous system progression in patients with EGFR-positive non-small cell lung cancer.

Tarlatamab 10 mg showed responses in patients with previously treated small cell lung cancer, and no new safety signals were observed.

At 2-year follow-up, patients with relapsed/refractory multiple myeloma treated with teclistamab achieved a median progression-free survival of 12.5 months with a median duration of response of 24 months.

Tumor mutation burden was linked with improved survival while some alterations were linked with inferior outcomes from treatment with enfortumab vedotin for urothelial carcinoma.

With 30 months additional follow-up on the EMPOWER-Cervical 1 trial, cemiplimab monotherapy showed efficacy in patients with metastatic cervical cancer.

Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.

There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.

Cabozantinib administered in the neoadjuvant setting to patients with advanced renal cell carcinoma may be beneficial, but more research is needed to confirm.

In subjects with recurrent hepatocellular carcinoma who underwent liver transplant, both progression-free survival and overall survival were prolonged with manageable adverse events.

Patients with relapsed/refractory chronic lymphocytic leukemia experienced progression-free survival benefit with acalabrutinib versus the standard of care, and therapy was effective out to 3 years in the ASCEND trial.

Tisagenlecleucel showed similar efficacy outcomes and a more favorable safety profile in real-world data of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia versus the ELIANA trial.